相关实验视频

Updated: Jan 13, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

针对性类风湿性关节炎治疗使用智能氧化反应性JAK抑制

Yeonju Boo¹, Sangmin Lee¹, Seohee Lee¹

¹Department of Chemistry, Pohang University of Science and Technology (POSTECH), 77 Cheongam-Ro, Nam-Gu, Pohang, Gyeongbuk, 37673, Republic of Korea.

Advanced healthcare materials

|October 29, 2025

概括

诺-托法是一种新型的氧化 (NO) 敏感的简氏激酶 (JAK) 抑制剂,通过选择性地激活炎症部位,有效治疗类风湿性关节炎 (RA). 与传统的JAK抑制剂相比,这种有针对性的方法降低了全身毒性.

科学领域:

免疫学免疫学免疫学
药理学药理学是指药理学的学科.
药物发现药物发现药物发现

背景情况:

类风湿性关节炎 (RA) 涉及慢性突炎,导致关节损伤.
目前的Janus激酶 (JAK) 抑制剂,如托法西替尼 (Tofa),由于广泛的免疫抑制,可能会导致系统性毒性.

研究的目的:

开发NOR-Tofa,一种对氧化 (NO) 敏感的JAK抑制剂结合物,用于炎症关节的向激活.
在RA的临床前模型中评估NOR-Tofa的疗效和安全性.

主要方法:

合成和结构性特征的NOR-Tofa,证实了NO反应和JAK抑制.
评估了NOR-Tofa在体外对LPS刺激的巨细胞中JAK-STAT信号和细胞因子表达的影响.
在原诱导关节炎 (CIA) 鼠标模型中评估了NOR-Tofa的体内治疗疗效和安全性.

主要成果:

在NO介导激活后,NOR-Tofa证明了强大的JAK抑制.
在体外,NOR-Tofa抑制了促炎性细胞因子表达.
在体内,NOR-Tofa显著缓解了关节炎症状,保持了关节结构,并显示了剂量依赖的疗效.
与托法西提尼布相比,药物动力学和毒性研究显示,全身暴露减少,安全性概况改善.

结论:

无反应性药物激活是针对性RA治疗的可行策略.
在治疗类风湿性关节炎方面,NOR-Tofa为传统的JAK抑制剂提供了更安全,更有选择性的替代品.

关键词:

这是JAK-STAT信号.抗炎疗法是一种抗炎疗法.氧化氧化是一种氧化.类风湿性关节炎类风湿性关节炎对刺激有反应的材料.

更多相关视频

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

相关概念视频

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Rheumatic Heart Disease III: Medical Management

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...